AI generated
Aug 3, 2026, 13:03
Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A
Mohamed El Belghiti Alaoui, Independent Researcher, shared a post on LinkedIn:
“AAV Gene Therapy (Factor VIII) for Hemophilia A.
Consider that a cure for the once‑incurable bleeding disorder Hemophilia A is now in clinical trials, offering hope beyond lifelong infusions.
We are shifting from merely managing bleeding episodes to rewriting patients’ biology, enabling their own cells to produce factor VIII continuously.
- Standard Hemophilia A care requires frequent factor VIII infusions, causing inhibitor formation, venous access challenges, and prohibitive costs.
- AAV vector delivers functional F8 gene to hepatocytes, enabling continuous endogenous factor VIII production and durable hemostasis.
- Approval would provide a one‑time infusion, eliminating lifelong prophylaxis and dramatically improving patient quality of life.
Would you trust this one‑time gene therapy for yourself or a loved one?”
Stay updated with Hemostasis Today.
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation
-
Sep 14, 2026, 20:48Valerie Dehondt: Nutritional Anemia Is Associated With Increased Risk of Severe COPD Exacerbations
-
Sep 14, 2026, 20:46Nupur Choudhury: Exploring AI-Based Detection of Anemia Using Eye and Fingernail Images
-
Sep 14, 2026, 20:44Shamee Shastry: Chart Before You Chase – Diagnosing Drug-Induced Hemolytic Anemia
-
Sep 14, 2026, 20:43David Reiner: Blood Tests That Can Reveal Nutrition Clues
-
Sep 14, 2026, 20:40Giuseppe Biondi Zoccai: Balancing Thrombosis and Bleeding in Acute MI With Hemophilia A
-
Sep 14, 2026, 20:39Kemal Karaagac: Kounis Syndrome as a Possible Cause of Very Late Stent Thrombosis